Study to Evaluate the Effect of Shumu Liujunzi Decoction combined with Endoscopic Treatment on the Quality of Life and Clinical Outcomes in Patients with Type 1 Gastric Neuroendocrine Tu
- Conditions
- Type 1 gastric neuroendocrine tumor
- Registration Number
- ITMCTR2200006581
- Lead Sponsor
- China-Japan Friendship Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
(1)Age = 18 years old
(2)According to the WHO (5th) classification and grading standards for gastrointestinal / hepatobiliary pancreatic neuroendocrine tumors in 2019, combined with the CSCO guidelines for diagnosis and treatment of neuroendocrine tumors (2021 Edition), type 1 g-nets were diagnosed: gastric neuroendocrine tumors (netg1 or netg2) with good differentiation were pathologically diagnosed. Serum gastrin was elevated, gastric parietal cell antibodies were positive, internal factor antibodies were positive, vitamin B12 was deficient, and gastroscopy showed multiple and polypoid lesions, Gastroscopy and pathology suggested (autoimmune) atrophic gastritis, HP (-), exclusion type 2 g-nets.
(3)Informed consent was signed.
(1)Have a history of malignant tumors of other parts and types
(2)Have a history of gastric surgery
(3)Taking proton pump inhibitors and H2 receptor blockers for at least 3 months
(4)Combined with serious diseases that affect the evaluation of the study
(5)Participated in clinical research of other drugs within 3 months before participating in the project
(6)Patients in preparation for pregnancy
(7)Pregnant or lactating women.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recurrence rate of the Tumor;
- Secondary Outcome Measures
Name Time Method Changes of pathological grade in gastroscopic biopsy;Changes of endoscopic grading of atrophic gastritis;Improvement degree of EORTCQLQ–GI.NET21 scale;Recurrence time of the Tumor;Improvement degree of QLQ-C30 scale;Improvement of TCM symptom scores;